Target intelligence / Profile preview

Adenosine deaminase RNA-specific B1 (ADAR2) (ADAR2)

Target
ADAR2
Molecular classification
Enzyme, Hydrolase, RNA-binding protein
01

Overview

Adenosine deaminase RNA-specific B1 (ADAR2), also known as Double-stranded RNA-specific editase 1, is a critical enzyme that catalyzes the post-transcriptional conversion of adenosine to inosine (A-to-I) within double-stranded RNA (dsRNA) [1, 2]. This RNA editing process is essential for generating molecular diversity, as inosine is recognized as guanosine by the cellular machinery, leading to amino acid substitutions and altered RNA processing [8, 10]. ADAR2 is primarily expressed in the central nervous system, where its most vital function is the site-specific editing of the GRIA2 (GluA2) subunit of AMPA receptors; this editing at the Q/R site is necessary to prevent calcium permeability and subsequent excitotoxic neuronal death [11, 12]. Pathologically, the loss or downregulation of ADAR2 activity is strongly linked to neurodegenerative conditions such as Amyotrophic Lateral Sclerosis (ALS) and certain forms of epilepsy, as well as the progression of malignant tumors like glioblastoma [13, 19]. In the context of drug development, ADAR2 is not only a target for restoration in neurodegeneration but also a key effector for novel RNA-editing therapeutics, such as ADAR-recruiting oligonucleotides, which aim to correct genetic mutations in vivo [13, 15]. While no small-molecule inhibitors or activators are currently FDA-approved, research is ongoing to develop selective modulators and delivery systems for RNA-based tools [3, 13]. Therapeutic challenges include the potential for widespread off-target editing and the risk of disrupting essential brain functions, making precise targeting and safety monitoring critical [11, 15]. The enzyme requires inositol hexakisphosphate (IP6) as a buried cofactor for its catalytic activity, which has been a focus for structural studies and drug design [19].

Other names
ADARB1RED1DRADA2Double-stranded RNA-specific editase 1RNA-editing deaminase 1RNA-editing enzyme 1dsRNA adenosine deaminase
02

Mechanism of action

Hydrolytic deamination of adenosine to inosine in double-stranded RNA

03

Biological functions

RNA editingA-to-I conversionRegulation of neurotransmissionAlternative splicing
04

Disease associations

Amyotrophic lateral sclerosisEpilepsyGlioblastomaAstrocytomaIntellectual disability
05

Safety considerations

Off-target RNA editingNeurotoxicityExcitotoxicity due to unedited GRIA2
06

Interacting drugs

Inositol hexakisphosphate

3 more in the full profile.

07

Biomarkers

GRIA2 Q/R editing levelHTR2C editing pattern

Beyond the preview

Go deeper on Adenosine deaminase RNA-specific B1 (ADAR2) (ADAR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adenosine deaminase RNA-specific B1 (ADAR2) (ADAR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call